Chemometec — Marts 2022
-
Herligt…med lidt medvind igen…skal 850 snart testes?
-
J&J has set high expectations for Carvykti. The pharma predicts peak annual sales of greater than $5 billion, or about one-tenth of what its entire pharmaceutical business earned last year.
https://www.biopharmadive.com/news/johnson-johnson-legend-carvykti-myeloma-fda-approval/619430/ -
Godkendelsen giver helt klart anledning til en større bestilling fra Janssen. Mit bud er at de umiddelbart vil blive bestilt mellem 30 og 50 stk NC200/202 + forbrugsvare ca 6 mil kr. Medfølgende service kontrakter skæpper også godt i kassen, dog successiv. Forårs opjustering er hermed så godt som garanteret.
-
Så sker der endelig noget….mon ikke shorterne begynder at trække i land….aktien er dyr, men potentialet er også meget stort, så mon ikke vi snart skal se en 4 cifrede kurs.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind
Stort tack för den info. Då kan vi nog räkna med att ChemoMetec finns med.